Free Trial
NASDAQ:AXSM

Axsome Therapeutics Q3 2025 Earnings Report

Axsome Therapeutics logo
$122.52 +3.81 (+3.21%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$121.88 -0.64 (-0.52%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.80
Beat/Miss
N/A
One Year Ago EPS
N/A

Axsome Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$162.96 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Axsome Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Monday, November 3, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Axsome Therapeutics Earnings Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
FY2027 Earnings Estimate for AXSM Issued By Leerink Partnrs
See More Axsome Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Axsome Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Axsome Therapeutics and other key companies, straight to your email.

About Axsome Therapeutics

Axsome Therapeutics (NASDAQ:AXSM) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates. AXS-05, a first-in-class oral investigational therapy combining dextromethorphan and bupropion, received U.S. Food and Drug Administration (FDA) approval for the treatment of major depressive disorder in 2021 and for agitation associated with Alzheimer’s disease. AXS-07, a combination of meloxicam and rizatriptan for acute migraine, gained FDA approval in 2023. The company is also advancing AXS-12 for narcolepsy and idiopathic hypersomnia under FDA review, as well as AXS-14, a proprietary formulation of esreboxetine, targeting fibromyalgia and related chronic pain conditions.

Founded in 2012 and headquartered in New York City, Axsome Therapeutics conducts its research and development activities primarily in the United States. The company’s leadership team is led by President and Chief Executive Officer Herriot Tabuteau, M.D., who brings extensive experience in neurologic and psychiatric drug development. Under his guidance, Axsome has advanced multiple clinical programs through crucial regulatory milestones and continues to collaborate with academic institutions and contract research organizations to support its growth strategy.

View Axsome Therapeutics Profile

More Earnings Resources from MarketBeat